中晚期肝细胞癌的局部治疗联合系统治疗研究进展
摘要：我国大部分肝细胞癌患者就诊时已处于疾病的中晚期阶段，单一治疗方案客观缓解率较低，而联合治疗明显提高了中晚期肝细胞癌患者的客观缓解率，延长了患者的生存期。本文就近年来中晚期肝细胞癌局部治疗联合系统治疗的最新研究进展进行详细阐述。关键词：癌， 肝细胞； 化学栓塞， 治疗性； 分子靶向治疗基金项目：江苏省卫健委重点科研项目（ZD2021061）
Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma
CAO Bailu， AI Min， HUANG Ping， YANG Yongfeng. （Department of Hepatology， Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital， Nanjing 210003， China）
Corresponding author：YANG Yongfeng， yyf1979@163.com （ORCID：0000-0002-0942-4833）
Abstract：Most patients with hepatocellular carcinoma （HCC） have reached the advanced stage at the time of diagnosis in China， and a single treatment regimen tends to have a low objective response rate （ORR）， while combined therapy can significantly increase the ORR of patients with advanced HCC and prolong their survival time. The article elaborates on the latest research advances in the efficacy of local treatment combined with systemic therapy for advanced HCC.
Key words：Carcinoma， Hepatocellular； Chemoembolization， Therapeutic； Molecular Targeted Therapy
Research funding：Key Program of Jiangsu Commision of Health （ZD2021061）
肝细胞癌（HCC）是全世界最常见的恶性肿瘤之一，每年死亡率位居第2位，仅次于胰腺癌［1］。（剩余14111字）